Agenus Buy Rating Reaffirmed as Late-Stage Strategy Advances; $23 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.
Emily Bodnar, an analyst from H.C. Wainwright, has reaffirmed a Buy rating on Agenus with a price target of $23. This decision is based on the company's progress in expanding access to its botensilimab and balstilimab combination, along with the initiation of the BATTMAN Phase 3 study for refractory metastatic colorectal cancer. The trial's efficient enrollment and FDA-endorsed design are expected to support potential U.S. approval. With secured capital and manufacturing support, Agenus is positioned to execute its late-stage strategy effectively.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments